MX363226B - Formulaciones de anticuerpos. - Google Patents
Formulaciones de anticuerpos.Info
- Publication number
- MX363226B MX363226B MX2014004992A MX2014004992A MX363226B MX 363226 B MX363226 B MX 363226B MX 2014004992 A MX2014004992 A MX 2014004992A MX 2014004992 A MX2014004992 A MX 2014004992A MX 363226 B MX363226 B MX 363226B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody formulations
- formulations
- antibody
- methods
- including pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La presente invención se refiere a una formulación que comprende un anticuerpo anti-IL13 en una tampón de acetato de histidina, Ph DE 5.4 A 6.0, en donde la formulación no comprende arginina, en donde la concentración de anticuerpo en la formulación es de al menos de 100 mg/Ml y la viscosidad de la formulación es inferior a 15 centipoise (Cp) A 25°c, y en donde (i) el anticuerpo anti-IL13 comprende: a. una cadena pesada que tiene la secuencia de aminoácidos de SEQ ID NO: 10 y una cadena ligera que tiene tres CDRs de cadena ligera, CDR-L1 que tiene la secuencia de aminoácido de SEQ ID NO: 4, CDR-L2 que tiene la secuencia de aminoácidos de SEQ ID NO: 5, y CDR-L3 que tiene la secuencia de aminoácidos de SEQ ID NO: 6, b. una cadena ligera que tiene la secuencia de aminoácidos de SEQ ID NO: 14 y una cadena pesada que tiene tres CDRs de cadena pesada, CDR-H1 que tiene la secuencia de aminoácidos de SEQ ID NO: 1, CDR-H2 que tiene la secuencia de aminoácidos de SEQ ID NO: 2, y CDR-H3 que tiene la secuencia de aminoácidos de SEQ ID NO: 3; o c. una cadena pesada que tiene la secuencia de aminoácidos de SEQ ID NO: 10 y una cadena ligera que tiene la secuencia de aminoácidos de SEQ ID NO: 14, y (ii) la concentración de acetato de histidina en el tampón es de entre 5 Mm y 40 Mm.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553916P | 2011-10-31 | 2011-10-31 | |
| PCT/US2012/062572 WO2013066866A1 (en) | 2011-10-31 | 2012-10-30 | Antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014004992A MX2014004992A (es) | 2014-08-27 |
| MX363226B true MX363226B (es) | 2019-03-15 |
Family
ID=48192677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014004992A MX363226B (es) | 2011-10-31 | 2012-10-30 | Formulaciones de anticuerpos. |
| MX2019002979A MX2019002979A (es) | 2011-10-31 | 2014-04-24 | Formulaciones de anticuerpos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002979A MX2019002979A (es) | 2011-10-31 | 2014-04-24 | Formulaciones de anticuerpos. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10000562B2 (es) |
| EP (3) | EP3091029B1 (es) |
| JP (4) | JP6120452B2 (es) |
| KR (4) | KR20140084078A (es) |
| CN (4) | CN108704132A (es) |
| AR (2) | AR088579A1 (es) |
| AU (3) | AU2012332767C1 (es) |
| BR (1) | BR112014008864B1 (es) |
| CA (2) | CA2849210C (es) |
| DK (1) | DK3091029T3 (es) |
| ES (1) | ES2936387T3 (es) |
| FI (1) | FI3091029T3 (es) |
| HK (1) | HK1201857A1 (es) |
| HR (1) | HRP20230153T1 (es) |
| HU (1) | HUE061728T2 (es) |
| IL (2) | IL232053B (es) |
| LT (1) | LT3091029T (es) |
| MX (2) | MX363226B (es) |
| MY (2) | MY197851A (es) |
| PL (1) | PL3091029T3 (es) |
| PT (1) | PT3091029T (es) |
| RS (1) | RS63948B1 (es) |
| RU (1) | RU2665810C2 (es) |
| SG (1) | SG11201401903PA (es) |
| SI (1) | SI3091029T1 (es) |
| WO (1) | WO2013066866A1 (es) |
| ZA (2) | ZA201401779B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2013066426A2 (en) | 2011-06-24 | 2013-05-10 | Kci Licensing, Inc. | Reduced-pressure dressings employing tissue-fixation elements |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP5775974B2 (ja) | 2011-10-28 | 2015-09-09 | プロセナ バイオサイエンシーズ リミテッド | アルファシヌクレインを認識するヒト化抗体 |
| CN108704132A (zh) | 2011-10-31 | 2018-10-26 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
| EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
| WO2013112945A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
| WO2015038888A1 (en) * | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Methods and compositions comprising purified recombinant polypeptides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| WO2015079977A1 (ja) * | 2013-11-26 | 2015-06-04 | シャープ株式会社 | 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット |
| EP3129051A1 (en) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| SG11201705019PA (en) | 2014-12-23 | 2017-07-28 | Merz Pharma Gmbh & Co Kgaa | Botulinum toxin prefilled container |
| HUE063135T2 (hu) * | 2016-09-23 | 2023-12-28 | Hoffmann La Roche | IL-13 antagonisták alkalmazásai atópiás dermatitis kezelésére |
| WO2018131893A1 (ko) * | 2017-01-11 | 2018-07-19 | ㈜셀트리온 | 안정한 액체 제제 |
| JP2019048091A (ja) * | 2018-10-23 | 2019-03-28 | ニプロ株式会社 | デクスメデトミジン注射液を充填したプレフィルドシリンジ |
| JP7101418B2 (ja) * | 2019-01-02 | 2022-07-15 | エム アンド ジェイ サイエンティフィック エルエルシー | 光散乱検出器及び光散乱検出器のための方法 |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| JP2023502777A (ja) * | 2019-11-26 | 2023-01-25 | コメラ ライフ サイエンシズ，インコーポレイテッド | バイオポリマー製剤のための賦形剤化合物 |
| JP2023547621A (ja) * | 2020-10-22 | 2023-11-13 | アラコス インコーポレイテッド | 抗ｓｉｇｌｅｃ－８抗体製剤 |
| TW202317191A (zh) | 2021-07-16 | 2023-05-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
| TW202323291A (zh) | 2021-08-13 | 2023-06-16 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
| WO2023044313A1 (en) | 2021-09-15 | 2023-03-23 | Dermira, Inc. | Il-13 inhibitors for the treatment of prurigo nodularis |
| WO2023215769A1 (en) | 2022-05-05 | 2023-11-09 | Dermira, Inc. | Il-13 antibodies for the treatment of atopic dermatitis |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| NL8720442A (nl) | 1986-08-18 | 1989-04-03 | Clinical Technologies Ass | Afgeefsystemen voor farmacologische agentia. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| CA2150803C (en) | 1992-12-02 | 2006-01-31 | Henry Auer | Controlled release growth hormone containing microspheres |
| PT779806E (pt) | 1994-09-09 | 2001-02-28 | Takeda Chemical Industries Ltd | Preparacao de libertacao sustentada contendo um sal metalico de um peptido |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| PL184531B1 (pl) | 1995-06-07 | 2002-11-29 | Alkermes Inc | Kompozycja o opóźnionym uwalnianiu ludzkiego hormonu wzrostu do wytwarzania leku do terapii |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| RU2319503C2 (ru) * | 2001-11-07 | 2008-03-20 | Цитос Байотекнолоджи Аг | Композиция для иммунизации (варианты), способ ее получения и применение для лечения аллергических эозинофильных заболеваний |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| ATE394123T1 (de) | 2003-02-28 | 2008-05-15 | Ares Trading Sa | Flüssige formulierungen des tumornekrosefraktor- bindungsproteins tbp-1 |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| RU2332986C2 (ru) | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
| AR045614A1 (es) * | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
| SG10201900535UA (en) * | 2003-12-23 | 2019-02-27 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0616359B8 (pt) | 2005-09-30 | 2022-08-30 | Medimmune Ltd | Composição farmacêutica, processo para purificação de um anticorpo de il-13 e uso de uma composição farmacêutica contendo um anticorpo |
| EP2532678A1 (en) * | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| US7390786B2 (en) * | 2005-12-21 | 2008-06-24 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| PE20081610A1 (es) | 2007-01-09 | 2008-12-09 | Wyeth Corp | Formulaciones de anticuerpos anti-il-13 y usos de los mismos |
| CA2676881C (en) * | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| MX2011005643A (es) * | 2008-12-03 | 2011-09-27 | Astellas Deutschland Gmbh | Formas de dosificacion oral de bendamustina. |
| CA2754528A1 (en) * | 2009-03-06 | 2010-09-10 | Genetech, Inc. | Antibody formulation |
| EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
| ES2722201T3 (es) * | 2010-03-22 | 2019-08-08 | Hoffmann La Roche | Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas |
| JP2013525484A (ja) | 2010-05-03 | 2013-06-20 | ジェネンテック， インコーポレイテッド | タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法 |
| WO2012151199A1 (en) | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| CN108704132A (zh) * | 2011-10-31 | 2018-10-26 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
-
2012
- 2012-10-30 CN CN201810964732.0A patent/CN108704132A/zh active Pending
- 2012-10-30 WO PCT/US2012/062572 patent/WO2013066866A1/en active Application Filing
- 2012-10-30 FI FIEP16169916.0T patent/FI3091029T3/fi active
- 2012-10-30 CN CN201280053245.XA patent/CN104039826A/zh active Pending
- 2012-10-30 KR KR20147011246A patent/KR20140084078A/ko active Search and Examination
- 2012-10-30 RU RU2014116070A patent/RU2665810C2/ru active
- 2012-10-30 AU AU2012332767A patent/AU2012332767C1/en active Active
- 2012-10-30 KR KR1020197018310A patent/KR20190077127A/ko not_active Application Discontinuation
- 2012-10-30 PT PT161699160T patent/PT3091029T/pt unknown
- 2012-10-30 CN CN201810964731.6A patent/CN109078182B/zh active Active
- 2012-10-30 CN CN202210876554.2A patent/CN116077644A/zh active Pending
- 2012-10-30 KR KR1020177022308A patent/KR101994809B1/ko active IP Right Grant
- 2012-10-30 PL PL16169916.0T patent/PL3091029T3/pl unknown
- 2012-10-30 EP EP16169916.0A patent/EP3091029B1/en active Active
- 2012-10-30 RS RS20230095A patent/RS63948B1/sr unknown
- 2012-10-30 EP EP22208284.4A patent/EP4218937A3/en active Pending
- 2012-10-30 LT LTEP16169916.0T patent/LT3091029T/lt unknown
- 2012-10-30 HU HUE16169916A patent/HUE061728T2/hu unknown
- 2012-10-30 CA CA2849210A patent/CA2849210C/en active Active
- 2012-10-30 MY MYPI2018001912A patent/MY197851A/en unknown
- 2012-10-30 KR KR1020207015572A patent/KR102259829B1/ko active IP Right Grant
- 2012-10-30 EP EP12846324.7A patent/EP2773662A4/en not_active Withdrawn
- 2012-10-30 JP JP2014539136A patent/JP6120452B2/ja active Active
- 2012-10-30 DK DK16169916.0T patent/DK3091029T3/da active
- 2012-10-30 AR ARP120104056 patent/AR088579A1/es not_active Application Discontinuation
- 2012-10-30 CA CA3078979A patent/CA3078979C/en active Active
- 2012-10-30 MY MYPI2014001225A patent/MY187874A/en unknown
- 2012-10-30 MX MX2014004992A patent/MX363226B/es unknown
- 2012-10-30 HR HRP20230153TT patent/HRP20230153T1/hr unknown
- 2012-10-30 ES ES16169916T patent/ES2936387T3/es active Active
- 2012-10-30 SI SI201232018T patent/SI3091029T1/sl unknown
- 2012-10-30 SG SG11201401903PA patent/SG11201401903PA/en unknown
- 2012-10-31 BR BR112014008864-0A patent/BR112014008864B1/pt active IP Right Grant
-
2014
- 2014-03-11 ZA ZA2014/01779A patent/ZA201401779B/en unknown
- 2014-04-10 IL IL232053A patent/IL232053B/en active IP Right Grant
- 2014-04-23 US US14/259,882 patent/US10000562B2/en active Active
- 2014-04-24 MX MX2019002979A patent/MX2019002979A/es unknown
-
2015
- 2015-03-09 HK HK15102358.5A patent/HK1201857A1/xx unknown
-
2016
- 2016-06-08 JP JP2016114267A patent/JP6272950B2/ja active Active
- 2016-08-05 AU AU2016210757A patent/AU2016210757A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017202159A patent/JP2018048166A/ja not_active Withdrawn
-
2018
- 2018-06-07 US US16/002,932 patent/US10947307B2/en active Active
- 2018-09-19 AU AU2018232943A patent/AU2018232943B2/en active Active
-
2019
- 2019-03-11 ZA ZA2019/01490A patent/ZA201901490B/en unknown
- 2019-06-25 JP JP2019116979A patent/JP6921148B2/ja active Active
-
2020
- 2020-07-22 IL IL276234A patent/IL276234B/en unknown
-
2021
- 2021-02-04 US US17/167,754 patent/US20210155684A1/en active Pending
- 2021-11-24 AR ARP210103246A patent/AR124140A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002979A (es) | Formulaciones de anticuerpos. | |
| PH12019501931A1 (en) | Anti-pdl1 antibody formulations | |
| PH12019500176A1 (en) | Heterocyclic compounds and ther uses | |
| MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
| TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| PH12014501427A1 (en) | Anti-php-tau antibodies and their uses | |
| PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
| MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
| PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| CR20150046A (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| AU2013225533A8 (en) | Amido spirocyclic amide and sulfonamide derivatives | |
| MX2015010682A (es) | Nuevos conjugados de anticuerpos y usos de los mismos. | |
| MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
| MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| MX354988B (es) | Formulaciones de anticuerpo y metodos. | |
| AU2014227660A8 (en) | Ceftolozane antibiotic compositions | |
| AU2013225816A8 (en) | Compositions and methods for treating Type III Gaucher Disease | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης | |
| AU2013338098A8 (en) | Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof | |
| IN2014CN02585A (es) | ||
| MX366768B (es) | Tableta orodispersable de sildenafil y metodo para preparar la misma. | |
| MX2016001694A (es) | Formulacion de vacuna de sacarido. | |
| UA111824C2 (uk) | Лікарські форми рифаксиміну і їх застосування |